Surveyed Physicians Are Satisfied With the Value of Spiriva and Would Be Unwilling to Pay a Higher Price for the Convenience of a Single-Inhaler, Once-Daily LABA/LAMA Combination Therapy Unless it Offers Substantial Improvements in Efficacy, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Boehringer Ingelheim/Pfizer's Spiriva will retain Decision Resources' proprietary clinical gold standard status for the treatment of chronic obstructive pulmonary disease (COPD) through 2018. While some drugs in development for COPD hold promise, most have less favorable efficacy, safety and tolerability, and/or delivery features compared with Spiriva.

"Our survey of primary care physicians (PCPs) indicates that a drug's effect on quality of life improvement is the attribute that most influences PCPs' prescribing decisions in moderate to very severe chronic obstructive pulmonary disease," stated Decision Resources' Analyst Amy Whiting, Ph.D. "Clinical data and the opinions of interviewed thought leaders indicate that Spiriva has advantages over sales-leading GlaxoSmithKline's Advair/Seretide, GlaxoSmithKline/Mitsubishi Tanabe's Adoair on this attribute."

The new report entitled Chronic Obstructive Pulmonary Disease: Opportunity Exists for Combination Therapies that Offer Improved Convenience and Outcomes also finds that surveyed PCPs are reasonably satisfied with the value of Spiriva and would not be willing to pay a higher price for the convenience of a single-inhaler, once-daily long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy unless it offers substantial improvements in efficacy—particularly improvements in quality of life and symptoms as well as a reduction in the risk of mortality.

About the Report

Chronic Obstructive Pulmonary Disease: Opportunity Exists for Combination Therapies that Offer Improved Convenience and Outcomes is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Back to top

RELATED LINKS
http://www.decisionresources.com